Experienced business leader with career expertise in global and US marketing and customer engagement. Successfully led numerous multi-functional initiatives including company acquisition integration, billion-dollar product launches and business-model transformations. Known for strong leadership skills, strategic thinking, customer focus and sound judgment.AREAS OF EXPERTISE• Financial performance • Biotechnology• Global Vaccine Marketing• Product Launch• Commercial Strategy• Global Team Leadership• Business Transformation• Mergers & acquisitions• Pandemic readinessSELECT STRATEGIC ACCOMPLISHMENTS• Led the 2,000-employee network of GSK seasonal and pandemic influenza vaccines/antivirals operations including commercial, R&D, regulatory, manufacturing and distribution teams across North America, Europe, Asia Pacific and Latin America. Achieved four consecutive record-breaking seasons in sales and profit through strong span of influence and alignment from R&D through customer delivery.• Led GSK’s U.S. vaccine business unit to improve its delivery of customer value through multiple initiatives, leading and developing a 40-person marketing and access team. Motivated teams to meet or exceed all portfolio financial targets, growing from <$1 billion to >$5 billion.• Consistently tapped to lead product launches and transformations of underperforming organizations at Fortune 50 companies. Rejuvenated multiple businesses to deliver sustainable profitability long term. • Led global strategic and prelaunch planning for GSK’s shingles vaccine candidate with the goal of market leadership. Identified key success factors and innovative solutions for payers, consumers, physicians and retail pharmacies to ensure broad patient access and lifetime protection from the debilitating pain linked to shingles. • Built business and launch plans for the successful introduction of the first cervical cancer vaccine, GARDASIL®, resulting in the first U.S. vaccine to reach $1 billion in sales in one year.• Transformed GSK’s U.S. and Global influenza vaccines business from transactional commodity to differentiated, scientific leadership in four-strain protection. As a result, the franchise has achieved double-digit percentage growth and contributed to overall company revenue growth annually in the last six years. • Recognized for improving overall GSK and product differentiation versus competition through customer centricity, resulting in a share gain from 13% of the total US vaccine market to 16% over three years.